Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 244Melanoma 141Squamous Cell Carcinoma of Head and Neck 139Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 104Triple Negative Breast Neoplasms 96Neoplasms 91Lung Neoplasms 91Breast Neoplasms 81Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 47Ovarian Neoplasms 46Endometrial Neoplasms 46Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Prostatic Neoplasms 26Recurrence 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 24Glioblastoma 23Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric and Gastroesophageal Junction Adenocarcinoma × pembrolizumab × 1 year × Clear all
NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Yonsei University

Phase 1/2 Active not recruiting
75 enrolled
Gastrointestinal

Gastric and Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡